PURPOSE To assess the benefits of epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors as neoadjuvant/adjuvant therapies in locally advanced EGFR mutation …

Abstract Lessons Learned The findings of this prospective, single‐arm, phase II study
showed that neoadjuvant erlotinib was well tolerated and might improve the radical …

Background Neoadjuvant erlotinib and customized adjuvant therapy are appealing but
controversial. The purpose of this study was to evaluate the role of biomarker-guided …

9005 Background: ADJUVANT-CTONG1104, a randomized phase 3 trial showed adjuvant
gefitinib treatment significantly improved disease-free survival (DFS) vs standard doublet …

Background Adjuvant chemotherapy after radical resection of stage IIIA non-small-cell lung
cancer (NSCLC) has quite poor outcomes. We aimed to investigate whether adjuvant …

PURPOSE ADJUVANT-CTONG1104 (ClinicalTrials. gov identifier: NCT01405079), a
randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved …

Purpose The development of targeted therapy has introduced new options to improve
treatment outcome in selected patients. The objective of this prospective study was to …

PURPOSE To investigate the efficacy of gefitinib as an adjuvant therapy for non–small-cell
lung cancer patients with EGFR mutation. PATIENTS AND METHODS IMPACT …

Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) show
great efficacy in patients with advanced non-small cell lung cancer (NSCLC) with EGFR …

Purpose The role of neoadjuvant epidermal growth factor receptor (EGFR)-tyrosine kinase
inhibitor (TKI) targeted therapy for patients with EGFR-mutant non-small cell lung cancer …